(PharmaNewsWire.Com, June 14, 2017 ) Ulcerative Colitis (UC) is a type of chronic IBD that causes inflammation and ulcers in the innermost lining of the colon and rectum. As a result, the colon's ability to absorb water is decreased, which leads to progressive loosening of the stool, bloody stool, and sometimes cramping or abdominal pain, with urgency for bowel movement. Other associated symptoms of UC include loss of appetite, weight loss, fatigue, and anaemia in cases of severe bleeding. The exact causes or triggers of the disease are yet to be identified; however, it is known that in people with UC, the body's immune system mistakes bacteria, food, and other materials in the intestine for foreign substances and attacks the colon tissues, leading to chronic inflammation of the colon linings. UC is a relapsing, remitting chronic disease that requires life long medical management and patients. Attributing to unknown aetiology of UC, all current pharmacopoeia provide immunosuppressive, symptomatic relief, as no curative disease therapy is available yet. Based on disease location and severity, patients receive different treatment alternatives either for induction or maintenance of remission.
- The main driver for the UC market will be the launch of Celgene's first-in-class Sphingosine 1 Phosphate Receptor 1 (S1P1) modulator, ozanimod hydrochloride, in all 6MM. Launch of Pfizer's Xeljanz, Johnson and Johnson's Stelara (ustekinumab), Lipid Therapeutics' LT-02, and Roche's etrolizumab will also contribute to global UC market growth. - The major global barrier for the UC market will be the sales erosion of blockbuster biologic drugs for moderate to severe UC space due to launch and increasing use of anti-tumor necrosis factor (TNF) biosimilars over this forecast period. - In the future, the dynamics of the lucrative moderate to severe UC market will shift greatly from the historical strategy of developing biologic drugs, towards small molecule oral drugs. - The key market opportunities lie in addressing unmet needs through the development of oral agents with superior efficacy and safety profile, low cost, curative UC therapy as well as drugs that help minimise colorectal cancer risk.
Report Scope - Overview of UC, including epidemiology, aetiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. - Annualized UC therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025. - Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the UC therapeutics market. - Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs. - Analysis of the current and future market competition in the global UC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Inquire for Report at http://www.reportsweb.com/inquiry&RW0001740894/buying .
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
